Jim Scopa
Director/Board Member presso ALIGOS THERAPEUTICS, INC.
Patrimonio netto: 325 530 $ in data 31/03/2024
Profilo
James Paul Scopa is currently serving as a Director at Astute Medical, Inc., Adverum Biotechnologies, Inc., Aligos Therapeutics, Inc., DICE Molecules SV, Inc., and Neuron23, Inc. In the past, he held positions as a Director at TriVascular, Inc., Conatus Pharmaceuticals, Inc., Peplin, Inc., Kalidex Pharmaceuticals, Inc., MPM BioImpact, Inc., Nevro Corp., Trivascular Technologies, Inc., Trivascular2, Inc., Solasia Pharma KK, iPierian, Inc., True North Therapeutics, Inc., Semma Therapeutics, Inc., DICE Therapeutics, Inc., Blade Therapeutics, Inc., and Cash Reserve Fund, Inc. He also worked as a Principal at Thomas Weisel Partners LLC, Alex.
Brown & Sons, Inc., and Deutsche Bank Corp.
Mr. Scopa obtained an MBA from Harvard Business School, a graduate degree from Harvard Law School, and an undergraduate degree from Harvard College.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
28/02/2024 | 183 083 ( 0.25% ) | 179 421 $ | 31/03/2024 | |
07/02/2024 | 10 333 ( 0.05% ) | 146 109 $ | 31/03/2024 |
Posizioni attive di Jim Scopa
Società | Posizione | Inizio |
---|---|---|
ADVERUM BIOTECHNOLOGIES, INC. | Director/Board Member | 01/05/2019 |
ALIGOS THERAPEUTICS, INC. | Director/Board Member | 27/04/2021 |
Neuron23, Inc.
Neuron23, Inc. Miscellaneous Commercial ServicesCommercial Services Neuron23, Inc. is a clinical-stage biotechnology company based in an undisclosed location. The American company's focus areas are neurodegenerative diseases, neuroinflammatory diseases, and systemic autoimmune and inflammatory diseases. Neuron23 combines recent advances in human genetics with a state-of-the-art drug discovery and biomarker platform using advanced techniques in machine learning and artificial intelligence to advance therapeutics for devastating diseases. The company was founded by Adam Knight and Nancy E. Stagliano has been the CEO of the company since 2019. | Director/Board Member | - |
Astute Medical, Inc.
Astute Medical, Inc. Electronic Equipment/InstrumentsElectronic Technology Astute Medical, Inc. discovers and develops biomarkers for acute conditions and diseases. It develops protein biomarker-based diagnostics technology for high-risk medical conditions such as cerebrovascular injury, kidney injury, sepsis, abdominal pain, and acute coronary syndromes. The firm’s products include NephroCheck test and Astute140 meter kits. The company was founded by Christopher Richard Hibberd and Paul H. McPherson in 2007 and is headquartered in San Diego, CA. | Director/Board Member | - |
DICE Molecules SV, Inc.
DICE Molecules SV, Inc. Investment ManagersFinance DICE Molecules SV LLC engages in a biotechnology company. It focuses on the development of small moleculecompounds that act by unlocking protein-protein interfaces that have been intractable targets for orally bioavailable drugs. The company was founded by Pehr Harbury, Kevin Judice, John Bedbrook, and Phil Patten in 2013 and is headquartered in South San Francisco, CA. | Director/Board Member | 01/11/2020 |
Precedenti posizioni note di Jim Scopa
Società | Posizione | Fine |
---|---|---|
Blade Therapeutics, Inc.
Blade Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Blade Therapeutics, Inc. offers anti-fibrotic therapies to meet unserved patient needs. Its product portfolio is to address various fibrotic diseases and their underlying pathophysiology. The company was founded by Hal Dietz and Wendye R. Robbins and is headquartered in South San Francisco, CA. | Director/Board Member | 01/09/2023 |
DICE THER | Director/Board Member | 09/08/2023 |
HISTOGEN INC. | Director/Board Member | 12/09/2018 |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Private Equity Investor | 01/06/2017 |
░░░░░░░░░░░ ░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Formazione di Jim Scopa
Harvard Business School | Masters Business Admin |
Harvard Law School | Graduate Degree |
Harvard College | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 4 |
---|---|
NEVRO CORP. | Health Technology |
SOLASIA PHARMA K.K. | Health Technology |
ADVERUM BIOTECHNOLOGIES, INC. | Health Technology |
ALIGOS THERAPEUTICS, INC. | Health Technology |
Aziende private | 19 |
---|---|
Cash Reserve Fund, Inc.
Cash Reserve Fund, Inc. Investment Trusts/Mutual FundsMiscellaneous Cash Reserve Fund, Inc. operates as an open-end investment fund trust. The fund offers prime, treasury and tax-free series. The fund was established in 1990 and is headquartered in New York, NY. | Miscellaneous |
TriVascular, Inc.
TriVascular, Inc. Medical SpecialtiesHealth Technology TriVascular, Inc. develops and manufactures medical devices. It provides devices and procedures for treating abdominal aortic aneurysms and endovascular grafts. The company was founded by Michael V. Chobotov, Robert G. Whirley, and Joseph W. Humphrey in 1998 and is headquartered in Irvine, CA. | Health Technology |
Conatus Pharmaceuticals, Inc.
Conatus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Conatus Pharmaceuticals, Inc. is a biotechnology company that focuses on the development and commercialization of novel medicines to treat chronic diseases. The firm engages in developing emricasan, an orally active pan-caspase inhibitor, for the treatment of patients with chronic liver disease and is designed to reduce the activities of human caspases. It also develops CTS-2090, an orally active selective caspase inhibitor, for diseases involving inflammasome pathways. The company was founded by Alfred P. Spada, Jennifer Giottonini Cayer, and Steven J. Mento on July 13, 2005 and is headquartered in San Diego, CA. | Health Technology |
Peplin, Inc.
Peplin, Inc. Pharmaceuticals: MajorHealth Technology Peplin, Inc. develops drugs and pharmaceutical products. The company was founded by James Harrison Aylward in 1998 and is headquartered in Emeryville, CA. | Health Technology |
Astute Medical, Inc.
Astute Medical, Inc. Electronic Equipment/InstrumentsElectronic Technology Astute Medical, Inc. discovers and develops biomarkers for acute conditions and diseases. It develops protein biomarker-based diagnostics technology for high-risk medical conditions such as cerebrovascular injury, kidney injury, sepsis, abdominal pain, and acute coronary syndromes. The firm’s products include NephroCheck test and Astute140 meter kits. The company was founded by Christopher Richard Hibberd and Paul H. McPherson in 2007 and is headquartered in San Diego, CA. | Electronic Technology |
Kalidex Pharmaceuticals, Inc.
Kalidex Pharmaceuticals, Inc. BiotechnologyHealth Technology Kalidex Pharmaceuticals, Inc. develops antibiotics for the treatment of serious infections. Its lead development candidate KPI-10 is a next-generation fluoroquinolone against a range of important gram-negative and gram-positive pathogens including multi-drug resistant strains and isolates resistant to currently available fluoroquinolones. The company was founded in 2010 by James Ge, Vernocn Jiang and George H. Talbot and is headquartered in Menlo Park, CA. | Health Technology |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Finance |
Thomas Weisel Partners LLC
Thomas Weisel Partners LLC Investment Banks/BrokersFinance Founded in 1998, Thomas Weisel Partners (TWP) is a broker/dealer headquartered in San Francisco with offices in New York City, Boston, Denver, Colorado and Palo Alto, California. The firm is a subsidiary of Thomas Weisel Partners Group, Inc. (Nasdaq: TWPG), a San Francisco-based investment banking firm. Their ultimate parent is Stifel Financial Corp. (NYSE: SF). TWP's investment banking, brokerage and equity research divisions serve emerging growth companies and institutional investors around the world. They are a member of the NYSE, the SIPC and FINRA. TWP specializes in the growth sectors of the economy with a particular focus on the consumer, energy, healthcare, Internet, media/telecommunications, metals/mining and technology sectors. Within the consumer sector, the firm focuses on: financial products, gaming/lodging, interactive market services, lifestyles/sports retailers, restaurants and hardlines and softlines retailing. TWP's global energy research is provided by analysts in three countries and covers the following trends: (1) fast-growing oil and natural gas producers in North America and worldwide (2) domestic and international energy service companies and (3) alternative energy technology and resource developers. Within the healthcare sector, TWP focuses on: biotechnology, diagnostics, healthcare information technology, pharmaceutical services, life science technology, medical devices and specialty pharmaceuticals. The firm's interest in the Internet, media and telecommunications sector include: Internet services, media, broadcasting and telecommunications services. Their focus within the metals and mining sector include: base metals, gold, precious metals and uranium. TWP's technology research focuses on: (1) applied technologies (2) communications components (3) core and wireless communications equipment (4) IP networking communications equipment (5) electronic supply chain (6) enterprise hardware (7) information and financial technology services (8) semiconductor capital equipment (9) broadline and specialty semiconductors (10) applications and communications software and (11) infrastructure software. TWP also provides value-added equities analysis across a variety of sectors including: industrials, financials, consumer, technology and healthcare. | Finance |
Alex. Brown & Sons, Inc. | Finance |
Deutsche Bank Corp.
Deutsche Bank Corp. Regional BanksFinance Part of Deutsche Bank AG, Deutsche Bank Corp. is a private company based in New York, NY. | Finance |
Trivascular Technologies, Inc.
Trivascular Technologies, Inc. Medical SpecialtiesHealth Technology Trivascular Technologies, Inc. operates as a medical device company developing and commercializing technologies to significantly advance minimally invasive treatment of abdominal aortic aneurysms. The company was founded on July 11, 2007 and is headquartered in Santa Rosa, CA. | Health Technology |
Trivascular2, Inc.
Trivascular2, Inc. Medical SpecialtiesHealth Technology Trivascular2, Inc. has pioneered numerous design and manufacturing technologies in pursuit of its commitment to providing optimal solutions for endovascular aortic repair (EVAR). TriVascular's initial product offerings are novel endovascular grafts focused on significantly advancing EVAR. Building upon partnerships with thought leading clinicians worldwide, its products are designed to address unmet clinical needs and expand the pool of patients who are candidates for EVAR. Based in Santa Rosa, California, TriVascular offers highly talented, motivated individuals the opportunity to positively impact global healthcare. | Health Technology |
iPierian, Inc.
iPierian, Inc. Pharmaceuticals: MajorHealth Technology ierian, Inc. developed and manufactured biopharmaceutical products. The firm's lead antibody, IPN007, represents a new approach to treating neurodegenerative disease by targeting a novel form of secreted Tau protein. The company was founded in 2007 and is headquartered in South San Francisco, CA. | Health Technology |
DICE Therapeutics, Inc.
DICE Therapeutics, Inc. BiotechnologyHealth Technology DiCE Therapeutics, Inc. is a biopharmaceutical company, which designs and develops a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. The company was founded by J. Kevin Judice on August 14, 2013 and is headquartered in South San Francisco, CA. | Health Technology |
Blade Therapeutics, Inc.
Blade Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Blade Therapeutics, Inc. offers anti-fibrotic therapies to meet unserved patient needs. Its product portfolio is to address various fibrotic diseases and their underlying pathophysiology. The company was founded by Hal Dietz and Wendye R. Robbins and is headquartered in South San Francisco, CA. | Commercial Services |
DICE Molecules SV, Inc.
DICE Molecules SV, Inc. Investment ManagersFinance DICE Molecules SV LLC engages in a biotechnology company. It focuses on the development of small moleculecompounds that act by unlocking protein-protein interfaces that have been intractable targets for orally bioavailable drugs. The company was founded by Pehr Harbury, Kevin Judice, John Bedbrook, and Phil Patten in 2013 and is headquartered in South San Francisco, CA. | Finance |
Neuron23, Inc.
Neuron23, Inc. Miscellaneous Commercial ServicesCommercial Services Neuron23, Inc. is a clinical-stage biotechnology company based in an undisclosed location. The American company's focus areas are neurodegenerative diseases, neuroinflammatory diseases, and systemic autoimmune and inflammatory diseases. Neuron23 combines recent advances in human genetics with a state-of-the-art drug discovery and biomarker platform using advanced techniques in machine learning and artificial intelligence to advance therapeutics for devastating diseases. The company was founded by Adam Knight and Nancy E. Stagliano has been the CEO of the company since 2019. | Commercial Services |
True North Therapeutics, Inc.
True North Therapeutics, Inc. BiotechnologyHealth Technology True North Therapeutics, Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, and commercialization of first-in-class product candidates for complement-mediated diseases. The company was founded by Nancy E. Stagliano in 2013 and is headquartered in South San Francisco, CA. | Health Technology |
Semma Therapeutics, Inc.
Semma Therapeutics, Inc. BiotechnologyHealth Technology Semma Therapeutics, Inc. develops transformative therapies for patients who currently depend on insulin injections. It focuses on combining proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. The company was founded by Robert A. Millman, Walter A. Blättler, Felicia Pagliuca, Jeff Imbaro and Douglas A. Melton in 2015 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Jim Scopa